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BACKGROUND: Mucositis is a significant toxicity of cancer therapy with numerous systemic sequelae. The goal of this systematic review 
was to update the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) 
Clinical Practice Guidelines for the management of mucositis. METHODS: The literature was reviewed systematically to identify interven-
tions for mucositis. Studies were rated according to the presence of major and minor flaws according to previously published criteria. 
The body of evidence for each intervention and in each treatment setting was assigned a level of evidence based on previously published 
criteria. Guidelines were developed based on the level of evidence, with 3 possible guideline determinations: recommendation, sugges-
tion, or no guideline possible. RESULTS: The guideline covers evidence from 1197 publications related to oral or gastrointestinal mucosi-
tis. Thirteen new guidelines were developed for or against the use of various interventions in specific treatment settings, and 11 previous 
guidelines were confirmed after aa review of new evidence. Thirteen previously established guidelines were carried over because there 
was no new evidence for these interventions. CONCLUSIONS: The updated MASCC/ISOO Clinical Practice Guidelines for mucositis 
provide professional health caregivers with a clinical setting-specific, evidence-based tool to help with the management of mucositis in 
patients who have cancer. Cancer 2020;126:4423-4431. © 2020 The Authors. Cancer published by Wiley Periodicals LLC on behalf of 
American Cancer Society. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 
License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and 
no modifications or adaptations are made. 
KEYWORDS: cancer, gastrointestinal, guidelines, mucositis, Multinational Association of Supportive Care in Cancer and International 
Society for Oral Oncology (MASCC/ISOO), oral.
INTRODUCTION
Mucositis is a common complication of radiotherapy (RT), chemotherapy (CT), a combination of RT and CT (RT-
CT), and hematopoietic stem cell transplantation (HSCT). Mucositis is characterized by erythema and ulceration 
of the mucosal lining of the gastrointestinal (GI) tract. Oral mucositis (OM) is associated with pain, difficulty in 
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eating and swallowing, the need for enteral or paren-
teral nutrition, increased opioid consumption, and in-
terruptions to cancer therapy.1,2 In immunosuppressed 
patients, OM is associated with bacteremia, increased 
inpatient hospitalization duration, and higher 100-day 
mortality.1-3 GI mucositis is associated with nausea, 
vomiting, diarrhea, bloating, intestinal cramping, and 
anal pain.4
Extensive research has been conducted globally to 
prevent, treat, or alleviate the symptoms of mucositis. 
To make use of the plethora of findings in an educated 
manner in the clinic, a systematic approach to weigh-
ing the evidence and analyzing the clinical applicabil-
ity has been taken. The Multinational Association of 
Supportive Care in Cancer and International Society 
for Oral Oncology (MASCC/ISOO) conducted a sys-
tematic review and first developed guidelines in 2004.5 
The systematic review identified the interventions with 
the strongest evidence and specified the clinical setting 
in which these interventions are most likely to be effec-
tive. These guidelines were updated in 2009 and 2014 
by the members of the Mucositis Study Group of the 
MASCC/ISOO.6,7
Considering the tremendous growth in mucositis 
research since the last guideline update, the MASCC/
ISOO decided to perform a new systematic review and 
update the clinical guidelines. The goal of this endeavor is 
to provide clinicians with a set of interventions for muco-
sitis with strong evidence to support or refute their use in 
certain clinical circumstances.
MATERIALS AND METHODS
Our methods have been described in detail in a recent 
publication.8 Briefly, a search for relevant papers in-
dexed in the literature from January 1, 2011 to June 30, 
2016 was conducted using PubMed/Web of Science/
EMBASE, with publications selected for review based 
on clear criteria. In addition, randomized clinical trials 
(RCTs) published between July 2016 and June 2019 
were reviewed.
Articles were reviewed by 2 independent review-
ers, and data were extracted using a standard electronic 
form. Studies were scored for their level of evidence 
(LoE) based on the criteria reported by Somerfield and 
McCrae,9 and flaws were listed according the criteria 
reported by Hadorn et al.10 A study was considered to 
be well designed when no major flaws were identified 
according to the criteria of Hadorn et al. RCTs received 
the most attention, although non-RCTs were analyzed 
as supporting evidence. A single RCT was considered 
insufficient to develop a guideline.
Studies comparing an agent with placebo were 
considered for the efficacy analysis, which focused on 
4 types of effects: mucositis severity, mucositis dura-
tion, pain severity, and pain duration. Studies compar-
ing an agent with another active control were assessed 
separately.
Findings from the reviewed studies were merged 
with the evidence reviewed in the previous MASCC/
ISOO guideline update, thus covering the entire lit-
erature. Findings were then organized into the new 
guideline update based on the overall LoE for each in-
tervention. Guidelines were classified as follows: recom-
mendation, suggestion, or no guideline possible (NGP). 
Negative guidelines were based on evidence showing 
lack of efficacy and not indicating that the agent is 
harmful.
Guidelines were based on the following clinical set-
tings: 1) the aim of the intervention (prevention or treat-
ment), 2) the cancer treatment modality (RT, CT, RT-CT, 
or high-dose conditioning therapy for HSCT), and 3) the 
route of administration.
Because of the large volume of literature, the proj-
ect was divided into 8 sections: 1) basic oral care; 2) an-
ti-inflammatory; 3) photobiomodulation (laser and other 
light therapy); 4) cryotherapy; 5) antimicrobials, coating 
agents, anesthetics, and analgesics; 6) growth factors and 
cytokines; 7) natural and miscellaneous agents; and 8) all 
interventions for GI mucositis. The intervention keyword 
list for each section is detailed in the article that provides 
an overview of the methods.8
RESULTS
The literature search identified 14,690 articles, of which 
627 were retrieved for detailed evaluation. The evidence 
from these articles was merged with 570 articles that were 
included in the previous systematic reviews.7 Taken to-
gether, the guideline covers evidence from 1197 publica-
tions. The guidelines for each section are presented below. 
For more detailed results, including lists of all reviewed 
articles, please refer to the published article for each 
section.11-18
Guidelines that are new or were changed compared 
with the 2014 guidelines are discussed below and appear 
in Table 1. Guidelines for which there was new evidence 
but the statements remained unchanged appear in Table 1 
only. The 2014 guidelines for which there was no new 
evidence appear in Supporting Table 1.
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TABLE 1. Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology 
Clinical Practice Guidelines for Oral Mucositis
Section LoE Guideline Statement
BOC III • The panel suggests that implementation of multiagent combination oral care protocols is beneficial for the 
prevention of OM during CT.
III • The panel suggests that implementation of multiagent combination oral care protocols is beneficial for the 
prevention of OM during H&N RT.
III • The panel suggests that implementation of multiagent combination oral care protocols is beneficial for the 
prevention of OM during HSCT.
III • No guideline was possible regarding the use of professional oral care for the prevention of OM in patients with 
hematologic, solid, or H&N cancers because of limited and inconsistent data.
An expert opinion complements this guideline: Although there was insufficient evidence to support the use of profes-
sional oral care for OM prevention, the panel is of the opinion that dental evaluation and treatment as indicated 
before cancer therapy are desirable to reduce risk for local and systemic infections from odontogenic sources.
III • No guideline was possible regarding the use of patient education for the prevention of OM in patients with 
hematologic cancer during HSCT or CT because of limited and inconsistent data.
An expert opinion complements this guideline: The panel is of the opinion that educating patients about the ben-
efits of BOC strategies is still appropriate because this may improve self-management and adherence to the 
recommended oral care protocol during cancer treatment.
III • No guideline was possible regarding the use of saline or sodium bicarbonate rinses in the prevention or treat-
ment of OM in patients undergoing cancer therapy because of limited data.
An expert opinion complements this guideline: Despite the limited data available for both saline and sodium 
bicarbonate, the panel recognizes that these are inert, bland rinses that increase oral clearance, which may be 
helpful for maintaining oral hygiene and improving patient comfort.
III • The panel suggests that CHX not be used in the prevention of OM in patients undergoing H&N RT.
Anti-inflammatory agents I • The panel recommends benzydamine mouthwash for the prevention of OM in patients with H&N cancer receiv-
ing a moderate dose RT (<50 Gy).
II • The panel suggests the use of benzydamine mouthwash for the prevention of OM in patients with H&N cancer 
who receive RT-CT.
PBM I • The panel recommends the use of intraoral PBM therapy using low-level laser therapy for the prevention of OM 
in adult patients receiving HSCT conditioned with high-dose CT, with or without TBI, using one of the selected 
protocols listed in Table 2.
II • The panel recommends the use of intraoral PBM therapy using low-level laser therapy for prevention of OM in 
adults receiving RT to the H&N (without CT) (Table 2); safety considerations unique to patients with oral cancer 
should be considered.
I • The panel recommends the use of intraoral PBM therapy using low-level laser therapy for the prevention of OM 
in adults receiving RT-CT for H&N cancer (Table 2); safety considerations unique to patients with oral cancer 
should be considered.
• For all PBM guidelines, it is recommended that the specific PTPs of the selected protocol will be followed for 
optimal therapy.
Cryotherapy II • The panel recommends using oral cryotherapy to prevent OM in patients undergoing autologous HSCT when 
the conditioning includes high-dose melphalan.
II • The panel recommends using 30 min of oral cryotherapy to prevent OM in patients receiving bolus 5-FU CT 
during the infusion of the CT.
Antimicrobials, coating agents, 
anesthetics, and analgesics
III • Topical morphine 0.2% mouthwash is suggested for the treatment of OM-associated pain in patients with H&N 
cancer who receive RT-CT.
II • Sucralfate (combined topical and systemic) is not recommended for the prevention of OM-associated pain in 
patients with H&N cancer who receive RT.
II • Sucralfate (combined topical and systemic) is not recommended for the treatment of OM-associated pain in 
patients with H&N cancer who receive RT.
II • Sucralfate (combined topical and systemic) is not recommended for the treatment of OM-associated pain in 
patients with solid cancer who receive CT.
Growth factors and cytokines I • The use of KGF-1 intravenously is recommended for the prevention of OM in patients with hematologic cancer 
undergoing autologous HSCT with a conditioning regimen that includes high-dose CT and TBI.
II • The evidence suggests that topical GM-CSF should not be used for the prevention of OM in patients undergo-
ing HSCT.
Natural and miscellaneous I • The panel recommends against the use of glutamine (parenteral) for the prevention of OM in patients undergo-
ing HSCT.
II • The panel suggests oral glutamine for the prevention of OM in patients with H&N cancer who receive receiving 
RT-CT.
The suggestion is with caution because of the higher mortality rate seen in patients undergoing HSCT who receive 
parenteral glutamine.
II • Honey is suggested for the prevention of OM in patients with H&N cancer who receive treatment with either RT 
or RT-CT.
III • Chewing gum is not suggested for the prevention of OM in pediatric patients with hematological or solid cancer 
who receive CT.
Abbreviations: 5-FU, 5-fluorouracil; BOC, basic oral care; CHX, chlorhexidine; CT, chemotherapy; GM-CSF, granulocyte-macrophage colony–stimulating factor; 
Gy, grays; H&N, head and neck; HSCT, hematopoietic stem-cell transplantation; KGF-1, keratinocyte growth factor 1; LoE, level of evidence; OM, oral mucositis; 
PBM, photobiomodulation; PTPs, photobiomodulation therapy parameters; RT, radiotherapy; TBI, total body irradiation.
aFor previous guidelines that are unchanged, see Supporting Table 1.
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Basic Oral Care
Basic oral care (BOC) includes all routine actions per-
formed by the patient or care provider to reduce the bac-
terial load in the oral cavity, to prevent infections, and to 
provide comfort. This usually involves mechanical cleaning 
(tooth brushing, flossing), mouthwashes to reduce bacte-
rial build-up (bland rinses), and hydration and lubrication 
(applying moisturizing agents) to the oral mucosal surfaces.
In this guideline update, the guidelines on BOC 
were divided into 5 subtopics11:
1. Patient education — educational interventions desi-
gned to help patients understand the importance 
of oral care and to perform the recommended oral 
practices during cancer therapy (this class of inter-
vention is new to the guidelines);
2. Multiagent combination oral care protocols — these 
protocols serve to increase the awareness of patients 
and staff of the importance of good oral hygiene that 
may lead to fewer and less severe oral complications; 
typically, the protocols involved recommendations 
with regard to the timing, frequency, and products 
used, which included various combinations of bland 
mouth rinses, toothbrushes, and flossing procedures;
3. Professional oral care — protocols delivered by dental 
professionals before or during cancer treatment;
4. Saline — saline rinses were compared with other types 
of bland rinses and chlorhexidine (CHX) rinses;
5. Sodium bicarbonate — a mouthwash of sodium 
bicarbonate diluted in water was compared with other 
bland rinses and CHX rinses; and
6. Chlorhexidine — CHX rinses were compared with 
placebo rinses, bland mouth rinses, and other active-
agent rinses.
The literature on mixed-medication mouth rinses was 
reviewed but was excluded from analysis because of the 
heterogeneity of the ingredients.
Several suggestions were made regarding multia-
gent combination oral care protocols for the prevention 
of OM in patients during CT, RT to the head and neck 
(H&N), or HSCT (Table 1). Because the objective of 
these protocols was to increase awareness of the im-
portance of oral hygiene and enhance compliance with 
routine BOC rather than test the effect of a particu-
lar agent, we were able to formulate a suggestion for 
each population of patients with cancer despite the rel-
atively small number of RCTs for each patient category. 
Furthermore, this trend was supported by numerous 
comparative studies.
The suggestion against CHX for the prevention of 
OM in patients undergoing RT to the H&N was main-
tained (Table 1). To clarify, this guideline only refers to 
the effect of CHX on OM prevention; it does not exclude 
the other indications for CHX, such as prevention or 
treatment of oral infection. If CHX is indicated because 
of concurrent oral infection and OM, it is acceptable to 
use it for the oral infection. The new RCTs were based on 
another patient population (RT-CT for H&N cancer)19 
or for another aim (treatment for OM rather than preven-
tion of OM).20
BOC remains an important best practice for pa-
tients undergoing cancer treatments; however, as a re-
search area, there is limited evidence from high-quality, 
rigorous studies. This was confirmed when patients with 
cancer were grouped according to treatment. To prevent 
misinterpretation of the guideline, the panel expanded it 
with expert opinion for the following areas: professional 
oral care, patient education, and rinse with saline or so-
dium bicarbonate (Table 1). This approach was also used 
in the 2014 guidelines. In the current update, the phras-
ing differentiates between evidence-based guidelines and 
the panel’s expert opinions.
Anti-Inflammatory Agents
A new guideline was added for benzydamine12: a sugges-
tion for the prevention of OM in patients with H&N 
cancer receiving RT and CT (Table 1).
New data regarding other anti-inflammatory agents, 
such as celecoxib, irsogladine maleate, misoprostol, and re-
bamipide, were found. The evidence for each of these agents 
was insufficient to support a guideline. Actually, when the 
previous evidence was stratified according to the setting and 
mode of application for misoprostol, there were too few 
data to justify a positive or a negative guideline for a specific 
setting. Therefore, the 2014 suggestion against misopros-
tol mouthwash for the prevention of OM in patients with 
H&N cancer who received RT was reversed to NGP.
Photobiomodulation
The rapidly growing field of laser and light therapy using 
low-level energy to stimulate biologic responses has been 
named photobiomodulation (PBM).21 Numerous RCTs 
and non-RCTs have been published about the application 
of PBM for the management of OM. The guideline de-
termination was influenced by RCTs that met strict clini-
cal and scientific criteria; however, clinical studies with 
lower LoE were assessed and contributed to the guideline. 
Studies with nonreproducible PBM therapy parameters 
(PTPs) were excluded from guideline determination.
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The current guideline update has several new 
insights13:
1. A recommendation for the prevention of OM with 
intraoral PBM therapy in patients who undergo 
HSCT (Tables  1 and 2)13—the current systematic 
review reiterates the 2014 guidelines in this patient 
population and increases the range of PBM settings 
that may be used22;
2. A recommendation for the prevention of OM with 
intraoral PBM therapy in patients with cancer who 
receive H&N RT (without CT) (Tables 1 and 2)—this 
is an upgrade of the 2014 guidelines from a suggestion 
to a recommendation22;
3. A recommendation for the prevention of OM with 
intraoral PBM therapy in patients with cancer who re-
ceive H&N RT with CT (Tables 1 and 2)—this new 
guideline is based on recent evidence.
In addition to the understanding described in the 
guidelines above, the critical review identified several 
flawless studies suggesting that PBM could prevent 
OM in specific patient populations. These protocols 
are highlighted (Table  2) with a clarification that the 
PBM settings mentioned in these protocols should be 
followed exactly to optimize clinical efficacy. In other 
words, each of the 5 suggested protocols stands alone. 
Individual variations may be considered for a particular 
patient; however, it is unclear how this will affect the 
clinical outcome.
We identified several RCTs aimed at the treatment 
of OM in pediatric patients undergoing mixed RT/RT-
CT, mixed HSCT/CT, or CT for several types of cancer. 
The results were promising; however, it is too early to base 
a guideline on these findings.
Several authors suggested that PBM may have 
long-term carcinogenic effects.13,23 Recent long-term 
follow-up studies on patients treated with PBM for 
the prevention of OM showed no increase in can-
cer recurrence. However, the analysis of these data is 
challenging.24,25 Considering the conflicting evidence 
from animal models regarding the effect of PBM on 
tumor behavior, the clinician is advised to inform pa-
tients about the expected benefits and potential risks of 
PBM.23,26
Cryotherapy
Cryotherapy results in vasoconstriction of the superficial 
blood vessels, thereby limiting the delivery of cytotoxic 
drugs to the oral tissue and reducing damage to the oral 
mucosa. Considering that the cooling is temporary, this 
treatment is only applicable for cytotoxic protocols that 
are delivered over a short time or for cytotoxic agents with 
a short half-life.
The panel identified evidence to support a recom-
mendation guideline for 2 clinical situations (Table  1). 
The new evidence enhanced the LoE for HSCT and 
strengthened both 2014 guidelines.18
Antimicrobials, Coating Agents, 
Anesthetics, and Analgesics
New evidence was identified for the following agents: 
morphine (topical), sucralfate (topical/systemic), flu-
conazole (systemic), miconazole (topical and systemic), 
mucoadhesive hydrogel (topical; MuGard), polyvi-
nylpyrrolidone (topical; Gelclair), doxepin (topical), 
and fentanyl (transdermal).17 The new evidence sup-
ported the suggestion in favor of topical morphine 
(Table 1).17
New studies on sucralfate did not pertain to the 
clinical settings referred to in the 2014 guidelines. 
Accordingly, the recommendations against sucralfate 
for 3 clinical settings remained unchanged. A clarifica-
tion was added to the guideline explaining that it refers 
to the combined topical application and systemic ad-
ministration of sucralfate (Table 1). in contrast, a pre-
vious recommendation against the use of sucralfate for 
the prevention of CT-associated OM was reversed to 
NGP in the current guidelines. It should be noted that 
these guidelines do not refer to the new formulation of 
sucralfate that has become available (polymerized cross-
linked sucralfate).
In the previous review, a suggestion was made in 
favor of doxepin mouthwash and for transdermal fentanyl. 
Considering the stringent criteria needed for a guideline 
and the mixed study population in some of the relevant 
studies, the updated guideline was changed to NGP.
The previous 2014 recommendations against 
Iseganan, polymyxin, tobramycin, and amphotericin B 
(PTA) paste; and bacitracin, clotrimazole, and gentamicin 
(BCoG) lozenges remain unchanged because there were 
no new data (see Supporting Table 1).17
Growth Factors and Cytokines
New evidence was identified for the following agents: ke-
ratinocyte growth factor-1, granulocyte-colony stimulat-
ing factor, granulocyte-macrophage colony-stimulating 
factor, epidermal growth factor, and erythropoietin.27 
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The new evidence published for human recombi-
nant keratinocyte growth factor-1 did not change the 
2014 guideline for this agent (Table 1).28
The new data about granulocyte-macrophage col-
ony–stimulating factor addressed a novel clinical setting; 
therefore, the previous guideline has not been changed 
(Table 1).27
Natural and Miscellaneous Agents
New evidence about the effects of various vitamins, min-
erals, and nutritional supplements on OM was assessed, 
including glutamine, elemental diet, zinc, supersaturated 
calcium phosphate rinse, vitamin E, selenium, folinic 
acid, and calcitriol.
A recommendation against the use of parenteral glu-
tamine in patients who undergo HSCT for the preven-
tion of OM was determined (Table 1).15 The change from 
the 2014 guidelines was an elevation of the LoE from II 
to I after the publication of a well designed RCT.29 A new 
suggestion was made regarding oral glutamine tablets in 
patients with H&N cancer who received RT-CT for the 
prevention of OM (Table 1). This guideline is based on 
2 RCTs showing that a glutamine dose from 10 to 30 mg 
daily during RT-CT may prevent OM. This guideline 
for oral glutamine mentions the negative guideline for 
parenteral glutamine and advises caution because of the 
higher relapse and mortality rates reported in 1 study of 
patients who underwent HSCT and received parenteral 
glutamine.30
The previous suggestion made for zinc in the 2014 
MASCC/ISOO guidelines for patients with H&N cancer 
who received RT or RT-CT was reversed in the current 
guidelines to NGP.7,15,31
In this guideline update, supersaturated calcium 
phosphate was included in the Natural and Miscellaneous 
section. Because of conflicting evidence about this mouth-
wash in various populations of patients with cancer, no 
guideline was possible.15
Honey, applied topically and administered system-
ically, has been suggested for the prevention of OM in 
patients with H&N cancer who received either RT or RT-CT 
(Table 1). Some of the RCTs had a mixed patient population 
(RT and RT-CT), small sample size, and different sources for 
the honey; therefore, only a suggestion was possible.
New evidence was identified for several natural rem-
edies and herbs. However, it was insufficient to form a 
guideline (a list is available in Supporting Table 2).15
New evidence about saliva stimulants and artificial 
moistening agents was reviewed as part of this update.15 
The lubricating effect of saliva as well as the protective pro-
teins and growth factors in saliva (epidermal growth factor 
and fibroblast growth factor) could promote wound heal-
ing. However, there was sufficient evidence that chewing 
gum is not effective for the prevention of OM in pediatric 
patients with hematologic or solid cancers who received 
with CT. Therefore, a suggestion against chewing gum was 
made (Table 1). This guideline does not preclude the use 
of chewing gum for any other purpose: saliva production, 
flavor, refreshment, or simply pleasure.
The previous guidelines (suggestion against) for pi-
locarpine and pentoxifylline in specific settings remain 
valid (see Supporting Table 1).7
All Interventions for GI Mucositis
The suggestions in favor of probiotics and hyperbaric 
oxygen were maintained (Table 3).14 The 2014 guidelines 







Time per  
Spot, s
Energy Density 
(Fluence), J/cm2 Spot Size, cm2 No. of Sites Duration
HSCT 632.8 31.25 40 1.0 0.8 18 From the d after ces-
sation of condition-
ing for 5 d
650 1000b 2 2.0 0.04 54-70 From the first d of 
conditioning to d + 
2 post-HSCT (for 
7-13 d)
RT 632.8 24 125 3.0 1.00 12 Entire RT course
RT-CT 660 417b 10 4.2 0.24 72 Entire RT course
660 625b 10 6.2 0.04 69 Entire RT course
Abbreviations: CT, chemotherapy; HSCT, hematopoietic stem-cell transplantation; RT, radiotherapy.
aFor details, see Zadik et al, 2019.13
bThis involves a potential thermal effect; the clinician is advised to pay attention to the specific parameters.
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in favor of amifostine, octreotide, sucralfate enemas, and 
sulfasalazine and the 2014 guidelines against the use of 
oral 5-acetyl salicylic acid and related compounds (mesala-
zine and olsalazine), oral sucralfate, and misoprostol sup-
positories in specific treatment settings were unchanged 
(see Supporting Table 1).
New evidence was identified for antimicrobials (ci-
profloxacine and metronidazole), famotidine, a fat-mod-
ified diet, formalin, glutamine, fiber, palifermin, sodium 
butyrate, and steroid. Because of inadequate and/or 
conflicting evidence, no guideline was possible for these 
agents.14
DISCUSSION
The MASCC/ISOO guidelines for the management of 
mucositis are a weighted summary of the best available sci-
entific evidence, framed in a practical clinical context. This 
update of the guidelines was based on an extensive, system-
atic review using meticulous methods that contribute to 
the robustness of the conclusions. Thirteen new guidelines 
were delineated, 11 previous guidelines were confirmed 
after a review of new evidence, and 13 previously estab-
lished guidelines were carried over to this version because 
no new evidence was available for these interventions.
Some of the interventions reported in this system-
atic review have various formulas (eg, glutamine), may be 
absorbed differently, depending on the compound (eg, 
zinc), may be manufactured from various sources (eg, 
honey), or may be delivered over various time periods 
(eg, cryotherapy). These factors may influence the clinical 
outcome. To simplify the analysis and its implications the 
information was generalized. These differences have been 
clarified in the detailed articles.11-18,27
Furthermore, some of the interventions may only 
be available in certain geographic areas (eg, certain 
herbal compounds) or may have different regulations 
determined by local drug agencies (eg, PBM). Economic 
challenges also may play a role in the selection of the pre-
ferred treatment. Therefore, it is clear that the application 
of the guidelines will need to be adjusted according to the 
individual clinic’s considerations and patient’s preference.
In the 16 years since publication of the first MASCC/
ISOO Mucositis Guidelines, the landscape of mucositis 
research has changed.5 Over the years, we have noticed a 
dramatic increase in the number of interventions studied 
for mucositis and in the quality of the study design used 
to assess the efficacy of these interventions. Our knowl-
edge on the pathogenesis of OM has also improved.32 
Although we reviewed a large body of evidence, there are 
still clinical settings for which there is no recommended 
intervention. Until more research is available, pain relief, 
dietary support, and secondary infection prevention are 
key elements in patient management.
As the number of positive guidelines increases, 
it should be noted that they are not presented in order 
of preference. All effective interventions for the specific 
clinical setting described are reasonable. In addition, the 
guidelines do not preclude other interventions that work 
well in the hands of a clinician.
Evidently, the biggest step up in the search for ef-
fective therapy for mucositis was in the field of PBM.13 
The current guidelines are based on stronger evidence, 
address more clinical settings, and offer more PBM proto-
cols. Although the calibration of various PBM protocols 
was enigmatic, we advised that each protocol be applied 
as a whole. Research about the principles for calibration 
between various wavelengths and various PTPs will open 
the door for many more effective PBM protocols.
Other types of mucositis have recently been reported 
in association with targeted therapy and immunother-
apy. Although these types of mucositis meet the Medical 
Subject Heading definition of mucositis, they are not 
covered in the current set of clinical practical guidelines. 
A long-term OM complication of cancer therapy was re-
cently reported called chronic OM33 and is not addressed 
in this guidelines update.
The ultimate goal of these guidelines is to improve 
the supportive care for patients with cancer and provide 
directions for future trials. As new research is conducted, 
new evidence will become available. To this end, the 
Mucositis Study Group of the MASCC/ISOO plans to 
continue updating the guidelines periodically.
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